nodes	percent_of_prediction	percent_of_DWPC	metapath
Vorinostat—HDAC6—ovarian cancer	0.654	1	CbGaD
Vorinostat—HDAC2—oviduct—ovarian cancer	0.00249	0.026	CbGeAlD
Vorinostat—HDAC6—decidua—ovarian cancer	0.00195	0.0203	CbGeAlD
Vorinostat—HDAC4—uterine cervix—ovarian cancer	0.00177	0.0184	CbGeAlD
Vorinostat—HDAC3—myometrium—ovarian cancer	0.00173	0.0181	CbGeAlD
Vorinostat—HDAC4—decidua—ovarian cancer	0.00168	0.0175	CbGeAlD
Vorinostat—HDAC3—embryo—ovarian cancer	0.00167	0.0174	CbGeAlD
Vorinostat—HDAC1—myometrium—ovarian cancer	0.00159	0.0165	CbGeAlD
Vorinostat—NCOR1—uterine cervix—ovarian cancer	0.00154	0.016	CbGeAlD
Vorinostat—HDAC6—female reproductive system—ovarian cancer	0.00154	0.016	CbGeAlD
Vorinostat—HDAC1—embryo—ovarian cancer	0.00153	0.0159	CbGeAlD
Vorinostat—HDAC8—uterus—ovarian cancer	0.00151	0.0158	CbGeAlD
Vorinostat—HDAC11—decidua—ovarian cancer	0.00151	0.0157	CbGeAlD
Vorinostat—HDAC4—gonad—ovarian cancer	0.00148	0.0154	CbGeAlD
Vorinostat—HDAC4—uterus—ovarian cancer	0.00147	0.0153	CbGeAlD
Vorinostat—NCOR1—decidua—ovarian cancer	0.00147	0.0153	CbGeAlD
Vorinostat—HDAC6—female gonad—ovarian cancer	0.0014	0.0146	CbGeAlD
Vorinostat—HDAC8—female reproductive system—ovarian cancer	0.00136	0.0142	CbGeAlD
Vorinostat—HDAC3—uterine cervix—ovarian cancer	0.00135	0.014	CbGeAlD
Vorinostat—HDAC11—gonad—ovarian cancer	0.00133	0.0139	CbGeAlD
Vorinostat—HDAC4—female reproductive system—ovarian cancer	0.00132	0.0138	CbGeAlD
Vorinostat—HDAC11—uterus—ovarian cancer	0.00132	0.0138	CbGeAlD
Vorinostat—NCOR1—gonad—ovarian cancer	0.00129	0.0134	CbGeAlD
Vorinostat—HDAC8—bone marrow—ovarian cancer	0.00129	0.0134	CbGeAlD
Vorinostat—HDAC3—decidua—ovarian cancer	0.00128	0.0134	CbGeAlD
Vorinostat—NCOR1—uterus—ovarian cancer	0.00128	0.0134	CbGeAlD
Vorinostat—HDAC4—bone marrow—ovarian cancer	0.00125	0.013	CbGeAlD
Vorinostat—HDAC1—epithelium—ovarian cancer	0.00125	0.013	CbGeAlD
Vorinostat—HDAC6—testis—ovarian cancer	0.00124	0.0129	CbGeAlD
Vorinostat—HDAC8—female gonad—ovarian cancer	0.00124	0.0129	CbGeAlD
Vorinostat—HDAC1—uterine cervix—ovarian cancer	0.00123	0.0129	CbGeAlD
Vorinostat—HDAC8—vagina—ovarian cancer	0.00123	0.0128	CbGeAlD
Vorinostat—HDAC3—endometrium—ovarian cancer	0.00122	0.0127	CbGeAlD
Vorinostat—HDAC9—uterine cervix—ovarian cancer	0.00121	0.0127	CbGeAlD
Vorinostat—NR0B1—gonad—ovarian cancer	0.00121	0.0126	CbGeAlD
Vorinostat—HDAC4—female gonad—ovarian cancer	0.0012	0.0125	CbGeAlD
Vorinostat—HDAC11—female reproductive system—ovarian cancer	0.00119	0.0124	CbGeAlD
Vorinostat—HDAC1—decidua—ovarian cancer	0.00118	0.0123	CbGeAlD
Vorinostat—HDAC9—decidua—ovarian cancer	0.00116	0.0121	CbGeAlD
Vorinostat—NCOR1—female reproductive system—ovarian cancer	0.00115	0.012	CbGeAlD
Vorinostat—HDAC3—uterus—ovarian cancer	0.00112	0.0117	CbGeAlD
Vorinostat—HDAC1—endometrium—ovarian cancer	0.00112	0.0116	CbGeAlD
Vorinostat—HDAC8—testis—ovarian cancer	0.0011	0.0115	CbGeAlD
Vorinostat—NCOR1—bone marrow—ovarian cancer	0.00109	0.0113	CbGeAlD
Vorinostat—NR0B1—female reproductive system—ovarian cancer	0.00108	0.0113	CbGeAlD
Vorinostat—HDAC11—female gonad—ovarian cancer	0.00108	0.0113	CbGeAlD
Vorinostat—HDAC11—vagina—ovarian cancer	0.00107	0.0112	CbGeAlD
Vorinostat—HDAC4—testis—ovarian cancer	0.00107	0.0111	CbGeAlD
Vorinostat—NCOR1—female gonad—ovarian cancer	0.00105	0.0109	CbGeAlD
Vorinostat—HDAC1—gonad—ovarian cancer	0.00104	0.0108	CbGeAlD
Vorinostat—HDAC1—uterus—ovarian cancer	0.00103	0.0107	CbGeAlD
Vorinostat—HDAC9—uterus—ovarian cancer	0.00101	0.0105	CbGeAlD
Vorinostat—HDAC3—female reproductive system—ovarian cancer	0.00101	0.0105	CbGeAlD
Vorinostat—NR0B1—female gonad—ovarian cancer	0.000984	0.0103	CbGeAlD
Vorinostat—HDAC11—testis—ovarian cancer	0.000959	0.00999	CbGeAlD
Vorinostat—HDAC3—bone marrow—ovarian cancer	0.000953	0.00994	CbGeAlD
Vorinostat—NCOR1—testis—ovarian cancer	0.00093	0.00969	CbGeAlD
Vorinostat—HDAC1—female reproductive system—ovarian cancer	0.000925	0.00964	CbGeAlD
Vorinostat—HDAC3—female gonad—ovarian cancer	0.000919	0.00958	CbGeAlD
Vorinostat—HDAC3—vagina—ovarian cancer	0.000913	0.00952	CbGeAlD
Vorinostat—HDAC9—female reproductive system—ovarian cancer	0.00091	0.00948	CbGeAlD
Vorinostat—HDAC6—lymph node—ovarian cancer	0.000898	0.00936	CbGeAlD
Vorinostat—HDAC1—bone marrow—ovarian cancer	0.000873	0.0091	CbGeAlD
Vorinostat—NR0B1—testis—ovarian cancer	0.000873	0.0091	CbGeAlD
Vorinostat—HDAC9—bone marrow—ovarian cancer	0.000859	0.00895	CbGeAlD
Vorinostat—HDAC1—female gonad—ovarian cancer	0.000842	0.00877	CbGeAlD
Vorinostat—HDAC1—vagina—ovarian cancer	0.000837	0.00872	CbGeAlD
Vorinostat—HDAC9—female gonad—ovarian cancer	0.000828	0.00863	CbGeAlD
Vorinostat—HDAC3—testis—ovarian cancer	0.000815	0.00849	CbGeAlD
Vorinostat—HDAC8—lymph node—ovarian cancer	0.000797	0.0083	CbGeAlD
Vorinostat—HDAC4—lymph node—ovarian cancer	0.000774	0.00807	CbGeAlD
Vorinostat—HDAC2—embryo—ovarian cancer	0.000767	0.008	CbGeAlD
Vorinostat—HDAC1—testis—ovarian cancer	0.000747	0.00778	CbGeAlD
Vorinostat—HDAC9—testis—ovarian cancer	0.000734	0.00765	CbGeAlD
Vorinostat—HDAC11—lymph node—ovarian cancer	0.000695	0.00724	CbGeAlD
Vorinostat—NCOR1—lymph node—ovarian cancer	0.000674	0.00702	CbGeAlD
Vorinostat—HDAC2—epithelium—ovarian cancer	0.000626	0.00653	CbGeAlD
Vorinostat—HDAC2—uterine cervix—ovarian cancer	0.000621	0.00647	CbGeAlD
Vorinostat—HDAC2—decidua—ovarian cancer	0.000591	0.00616	CbGeAlD
Vorinostat—HDAC3—lymph node—ovarian cancer	0.000591	0.00616	CbGeAlD
Vorinostat—HDAC2—endometrium—ovarian cancer	0.000561	0.00585	CbGeAlD
Vorinostat—HDAC1—lymph node—ovarian cancer	0.000541	0.00564	CbGeAlD
Vorinostat—HDAC9—lymph node—ovarian cancer	0.000532	0.00555	CbGeAlD
Vorinostat—HDAC2—gonad—ovarian cancer	0.000521	0.00543	CbGeAlD
Vorinostat—HDAC2—uterus—ovarian cancer	0.000517	0.00539	CbGeAlD
Vorinostat—HDAC2—female reproductive system—ovarian cancer	0.000465	0.00485	CbGeAlD
Vorinostat—HDAC2—bone marrow—ovarian cancer	0.000439	0.00458	CbGeAlD
Vorinostat—HDAC2—female gonad—ovarian cancer	0.000423	0.00441	CbGeAlD
Vorinostat—HDAC2—vagina—ovarian cancer	0.000421	0.00438	CbGeAlD
Vorinostat—HDAC2—testis—ovarian cancer	0.000375	0.00391	CbGeAlD
Vorinostat—Embolism—Epirubicin—ovarian cancer	0.00035	0.00355	CcSEcCtD
Vorinostat—Pancytopenia—Vinorelbine—ovarian cancer	0.000348	0.00353	CcSEcCtD
Vorinostat—Neutropenia—Vinorelbine—ovarian cancer	0.000343	0.00348	CcSEcCtD
Vorinostat—Sepsis—Paclitaxel—ovarian cancer	0.000341	0.00346	CcSEcCtD
Vorinostat—Alopecia—Chlorambucil—ovarian cancer	0.000341	0.00345	CcSEcCtD
Vorinostat—Serum creatinine increased—Doxorubicin—ovarian cancer	0.000338	0.00343	CcSEcCtD
Vorinostat—Pulmonary embolism—Docetaxel—ovarian cancer	0.000333	0.00338	CcSEcCtD
Vorinostat—Weight decreased—Vinorelbine—ovarian cancer	0.000332	0.00336	CcSEcCtD
Vorinostat—Embolism—Doxorubicin—ovarian cancer	0.000324	0.00328	CcSEcCtD
Vorinostat—Acute coronary syndrome—Vinorelbine—ovarian cancer	0.000322	0.00327	CcSEcCtD
Vorinostat—Myocardial infarction—Vinorelbine—ovarian cancer	0.000321	0.00325	CcSEcCtD
Vorinostat—Anaemia—Chlorambucil—ovarian cancer	0.00031	0.00314	CcSEcCtD
Vorinostat—Chills—Topotecan—ovarian cancer	0.000308	0.00312	CcSEcCtD
Vorinostat—Angioedema—Chlorambucil—ovarian cancer	0.000307	0.00311	CcSEcCtD
Vorinostat—Alopecia—Topotecan—ovarian cancer	0.000303	0.00307	CcSEcCtD
Vorinostat—Dermatitis exfoliative—Paclitaxel—ovarian cancer	0.000303	0.00307	CcSEcCtD
Vorinostat—Leukopenia—Chlorambucil—ovarian cancer	0.0003	0.00304	CcSEcCtD
Vorinostat—Alopecia—Melphalan—ovarian cancer	0.000297	0.00301	CcSEcCtD
Vorinostat—Lethargy—Paclitaxel—ovarian cancer	0.000291	0.00295	CcSEcCtD
Vorinostat—Sepsis—Docetaxel—ovarian cancer	0.000289	0.00293	CcSEcCtD
Vorinostat—Muscle spasms—Topotecan—ovarian cancer	0.000287	0.00291	CcSEcCtD
Vorinostat—Abscess—Epirubicin—ovarian cancer	0.000284	0.00288	CcSEcCtD
Vorinostat—Anaemia—Topotecan—ovarian cancer	0.000276	0.0028	CcSEcCtD
Vorinostat—Angioedema—Topotecan—ovarian cancer	0.000273	0.00277	CcSEcCtD
Vorinostat—Infection—Chlorambucil—ovarian cancer	0.000272	0.00276	CcSEcCtD
Vorinostat—HDAC2—lymph node—ovarian cancer	0.000272	0.00284	CbGeAlD
Vorinostat—Anaemia—Melphalan—ovarian cancer	0.00027	0.00274	CcSEcCtD
Vorinostat—Thrombocytopenia—Chlorambucil—ovarian cancer	0.000268	0.00272	CcSEcCtD
Vorinostat—Leukopenia—Topotecan—ovarian cancer	0.000267	0.00271	CcSEcCtD
Vorinostat—Blood creatinine increased—Paclitaxel—ovarian cancer	0.000267	0.00271	CcSEcCtD
Vorinostat—Dehydration—Paclitaxel—ovarian cancer	0.000265	0.00269	CcSEcCtD
Vorinostat—Neoplasm malignant—Epirubicin—ovarian cancer	0.000263	0.00267	CcSEcCtD
Vorinostat—Abscess—Doxorubicin—ovarian cancer	0.000263	0.00266	CcSEcCtD
Vorinostat—Leukopenia—Melphalan—ovarian cancer	0.000262	0.00265	CcSEcCtD
Vorinostat—Anorexia—Chlorambucil—ovarian cancer	0.000261	0.00265	CcSEcCtD
Vorinostat—Cough—Topotecan—ovarian cancer	0.000261	0.00264	CcSEcCtD
Vorinostat—Hypokalaemia—Paclitaxel—ovarian cancer	0.00026	0.00263	CcSEcCtD
Vorinostat—Alopecia—Vinorelbine—ovarian cancer	0.000259	0.00263	CcSEcCtD
Vorinostat—Cough—Melphalan—ovarian cancer	0.000255	0.00259	CcSEcCtD
Vorinostat—Chest pain—Topotecan—ovarian cancer	0.000254	0.00258	CcSEcCtD
Vorinostat—Chest pain—Melphalan—ovarian cancer	0.000249	0.00252	CcSEcCtD
Vorinostat—Lethargy—Docetaxel—ovarian cancer	0.000247	0.0025	CcSEcCtD
Vorinostat—Neoplasm malignant—Doxorubicin—ovarian cancer	0.000244	0.00247	CcSEcCtD
Vorinostat—Infection—Topotecan—ovarian cancer	0.000242	0.00246	CcSEcCtD
Vorinostat—Gastrointestinal haemorrhage—Docetaxel—ovarian cancer	0.000242	0.00245	CcSEcCtD
Vorinostat—Thrombocytopenia—Topotecan—ovarian cancer	0.000239	0.00242	CcSEcCtD
Vorinostat—Decreased appetite—Chlorambucil—ovarian cancer	0.000238	0.00241	CcSEcCtD
Vorinostat—Infection—Melphalan—ovarian cancer	0.000237	0.0024	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000236	0.0024	CcSEcCtD
Vorinostat—Anaemia—Vinorelbine—ovarian cancer	0.000236	0.00239	CcSEcCtD
Vorinostat—Fatigue—Chlorambucil—ovarian cancer	0.000236	0.00239	CcSEcCtD
Vorinostat—Pancytopenia—Paclitaxel—ovarian cancer	0.000234	0.00237	CcSEcCtD
Vorinostat—Thrombocytopenia—Melphalan—ovarian cancer	0.000234	0.00237	CcSEcCtD
Vorinostat—Angioedema—Vinorelbine—ovarian cancer	0.000234	0.00237	CcSEcCtD
Vorinostat—Anorexia—Topotecan—ovarian cancer	0.000232	0.00236	CcSEcCtD
Vorinostat—Neutropenia—Paclitaxel—ovarian cancer	0.000231	0.00234	CcSEcCtD
Vorinostat—Upper respiratory tract infection—Paclitaxel—ovarian cancer	0.000229	0.00232	CcSEcCtD
Vorinostat—Leukopenia—Vinorelbine—ovarian cancer	0.000229	0.00232	CcSEcCtD
Vorinostat—Anorexia—Melphalan—ovarian cancer	0.000228	0.00231	CcSEcCtD
Vorinostat—Dehydration—Docetaxel—ovarian cancer	0.000225	0.00228	CcSEcCtD
Vorinostat—Pulmonary embolism—Epirubicin—ovarian cancer	0.000225	0.00228	CcSEcCtD
Vorinostat—Weight decreased—Paclitaxel—ovarian cancer	0.000223	0.00226	CcSEcCtD
Vorinostat—Cough—Vinorelbine—ovarian cancer	0.000223	0.00226	CcSEcCtD
Vorinostat—Hyperglycaemia—Paclitaxel—ovarian cancer	0.000223	0.00226	CcSEcCtD
Vorinostat—Chest pain—Vinorelbine—ovarian cancer	0.000218	0.00221	CcSEcCtD
Vorinostat—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.000217	0.0022	CcSEcCtD
Vorinostat—Body temperature increased—Chlorambucil—ovarian cancer	0.000217	0.00219	CcSEcCtD
Vorinostat—Myocardial infarction—Paclitaxel—ovarian cancer	0.000216	0.00219	CcSEcCtD
Vorinostat—Decreased appetite—Topotecan—ovarian cancer	0.000212	0.00215	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000211	0.00213	CcSEcCtD
Vorinostat—Fatigue—Topotecan—ovarian cancer	0.00021	0.00213	CcSEcCtD
Vorinostat—Constipation—Topotecan—ovarian cancer	0.000209	0.00211	CcSEcCtD
Vorinostat—Pulmonary embolism—Doxorubicin—ovarian cancer	0.000208	0.00211	CcSEcCtD
Vorinostat—Decreased appetite—Melphalan—ovarian cancer	0.000208	0.0021	CcSEcCtD
Vorinostat—Infection—Vinorelbine—ovarian cancer	0.000207	0.0021	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000206	0.00209	CcSEcCtD
Vorinostat—Fatigue—Melphalan—ovarian cancer	0.000206	0.00209	CcSEcCtD
Vorinostat—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000204	0.00207	CcSEcCtD
Vorinostat—Anorexia—Vinorelbine—ovarian cancer	0.000199	0.00202	CcSEcCtD
Vorinostat—Pancytopenia—Docetaxel—ovarian cancer	0.000199	0.00201	CcSEcCtD
Vorinostat—Asthenia—Chlorambucil—ovarian cancer	0.000197	0.00199	CcSEcCtD
Vorinostat—Neutropenia—Docetaxel—ovarian cancer	0.000196	0.00198	CcSEcCtD
Vorinostat—Sepsis—Epirubicin—ovarian cancer	0.000195	0.00198	CcSEcCtD
Vorinostat—Oedema peripheral—Paclitaxel—ovarian cancer	0.000195	0.00197	CcSEcCtD
Vorinostat—Pruritus—Chlorambucil—ovarian cancer	0.000194	0.00196	CcSEcCtD
Vorinostat—Body temperature increased—Topotecan—ovarian cancer	0.000193	0.00195	CcSEcCtD
Vorinostat—Weight decreased—Docetaxel—ovarian cancer	0.000189	0.00192	CcSEcCtD
Vorinostat—Diarrhoea—Chlorambucil—ovarian cancer	0.000187	0.0019	CcSEcCtD
Vorinostat—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000184	0.00186	CcSEcCtD
Vorinostat—Myocardial infarction—Docetaxel—ovarian cancer	0.000183	0.00185	CcSEcCtD
Vorinostat—Decreased appetite—Vinorelbine—ovarian cancer	0.000181	0.00184	CcSEcCtD
Vorinostat—Sepsis—Doxorubicin—ovarian cancer	0.000181	0.00183	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00018	0.00183	CcSEcCtD
Vorinostat—Fatigue—Vinorelbine—ovarian cancer	0.00018	0.00182	CcSEcCtD
Vorinostat—Constipation—Vinorelbine—ovarian cancer	0.000178	0.00181	CcSEcCtD
Vorinostat—Chills—Paclitaxel—ovarian cancer	0.000177	0.0018	CcSEcCtD
Vorinostat—Asthenia—Topotecan—ovarian cancer	0.000175	0.00177	CcSEcCtD
Vorinostat—Alopecia—Paclitaxel—ovarian cancer	0.000175	0.00177	CcSEcCtD
Vorinostat—Vomiting—Chlorambucil—ovarian cancer	0.000174	0.00177	CcSEcCtD
Vorinostat—Dermatitis exfoliative—Epirubicin—ovarian cancer	0.000173	0.00175	CcSEcCtD
Vorinostat—Pruritus—Topotecan—ovarian cancer	0.000173	0.00175	CcSEcCtD
Vorinostat—Asthenia—Melphalan—ovarian cancer	0.000171	0.00174	CcSEcCtD
Vorinostat—Pruritus—Melphalan—ovarian cancer	0.000169	0.00171	CcSEcCtD
Vorinostat—Dysgeusia—Paclitaxel—ovarian cancer	0.000168	0.00171	CcSEcCtD
Vorinostat—Diarrhoea—Topotecan—ovarian cancer	0.000167	0.00169	CcSEcCtD
Vorinostat—Lethargy—Epirubicin—ovarian cancer	0.000167	0.00169	CcSEcCtD
Vorinostat—Muscle spasms—Paclitaxel—ovarian cancer	0.000165	0.00168	CcSEcCtD
Vorinostat—Body temperature increased—Vinorelbine—ovarian cancer	0.000165	0.00167	CcSEcCtD
Vorinostat—Oedema peripheral—Docetaxel—ovarian cancer	0.000165	0.00167	CcSEcCtD
Vorinostat—Diarrhoea—Melphalan—ovarian cancer	0.000163	0.00166	CcSEcCtD
Vorinostat—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.000163	0.00165	CcSEcCtD
Vorinostat—Nausea—Chlorambucil—ovarian cancer	0.000163	0.00165	CcSEcCtD
Vorinostat—Dizziness—Topotecan—ovarian cancer	0.000161	0.00163	CcSEcCtD
Vorinostat—Dermatitis exfoliative—Doxorubicin—ovarian cancer	0.00016	0.00162	CcSEcCtD
Vorinostat—Anaemia—Paclitaxel—ovarian cancer	0.000159	0.00161	CcSEcCtD
Vorinostat—Angioedema—Paclitaxel—ovarian cancer	0.000157	0.00159	CcSEcCtD
Vorinostat—Vomiting—Topotecan—ovarian cancer	0.000155	0.00157	CcSEcCtD
Vorinostat—Syncope—Paclitaxel—ovarian cancer	0.000154	0.00156	CcSEcCtD
Vorinostat—Lethargy—Doxorubicin—ovarian cancer	0.000154	0.00156	CcSEcCtD
Vorinostat—Leukopenia—Paclitaxel—ovarian cancer	0.000154	0.00156	CcSEcCtD
Vorinostat—Blood creatinine increased—Epirubicin—ovarian cancer	0.000153	0.00155	CcSEcCtD
Vorinostat—Headache—Topotecan—ovarian cancer	0.000153	0.00155	CcSEcCtD
Vorinostat—Vomiting—Melphalan—ovarian cancer	0.000152	0.00154	CcSEcCtD
Vorinostat—Dehydration—Epirubicin—ovarian cancer	0.000152	0.00154	CcSEcCtD
Vorinostat—Loss of consciousness—Paclitaxel—ovarian cancer	0.000151	0.00153	CcSEcCtD
Vorinostat—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.000151	0.00153	CcSEcCtD
Vorinostat—Chills—Docetaxel—ovarian cancer	0.00015	0.00152	CcSEcCtD
Vorinostat—Cough—Paclitaxel—ovarian cancer	0.00015	0.00152	CcSEcCtD
Vorinostat—Asthenia—Vinorelbine—ovarian cancer	0.00015	0.00152	CcSEcCtD
Vorinostat—Hypokalaemia—Epirubicin—ovarian cancer	0.000149	0.00151	CcSEcCtD
Vorinostat—Alopecia—Docetaxel—ovarian cancer	0.000148	0.0015	CcSEcCtD
Vorinostat—Pruritus—Vinorelbine—ovarian cancer	0.000148	0.0015	CcSEcCtD
Vorinostat—Chest pain—Paclitaxel—ovarian cancer	0.000146	0.00148	CcSEcCtD
Vorinostat—Nausea—Topotecan—ovarian cancer	0.000145	0.00147	CcSEcCtD
Vorinostat—Dry mouth—Paclitaxel—ovarian cancer	0.000143	0.00145	CcSEcCtD
Vorinostat—Diarrhoea—Vinorelbine—ovarian cancer	0.000143	0.00145	CcSEcCtD
Vorinostat—Dysgeusia—Docetaxel—ovarian cancer	0.000143	0.00145	CcSEcCtD
Vorinostat—Nausea—Melphalan—ovarian cancer	0.000142	0.00144	CcSEcCtD
Vorinostat—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000141	0.00143	CcSEcCtD
Vorinostat—Dehydration—Doxorubicin—ovarian cancer	0.00014	0.00142	CcSEcCtD
Vorinostat—Muscle spasms—Docetaxel—ovarian cancer	0.00014	0.00142	CcSEcCtD
Vorinostat—Infection—Paclitaxel—ovarian cancer	0.000139	0.00141	CcSEcCtD
Vorinostat—Shock—Paclitaxel—ovarian cancer	0.000138	0.0014	CcSEcCtD
Vorinostat—Dizziness—Vinorelbine—ovarian cancer	0.000138	0.0014	CcSEcCtD
Vorinostat—Hypokalaemia—Doxorubicin—ovarian cancer	0.000137	0.00139	CcSEcCtD
Vorinostat—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000137	0.00139	CcSEcCtD
Vorinostat—Anaemia—Docetaxel—ovarian cancer	0.000135	0.00137	CcSEcCtD
Vorinostat—Pancytopenia—Epirubicin—ovarian cancer	0.000134	0.00136	CcSEcCtD
Vorinostat—Anorexia—Paclitaxel—ovarian cancer	0.000134	0.00136	CcSEcCtD
Vorinostat—Vomiting—Vinorelbine—ovarian cancer	0.000133	0.00134	CcSEcCtD
Vorinostat—Neutropenia—Epirubicin—ovarian cancer	0.000132	0.00134	CcSEcCtD
Vorinostat—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000131	0.00133	CcSEcCtD
Vorinostat—Headache—Vinorelbine—ovarian cancer	0.000131	0.00132	CcSEcCtD
Vorinostat—Syncope—Docetaxel—ovarian cancer	0.000131	0.00132	CcSEcCtD
Vorinostat—Leukopenia—Docetaxel—ovarian cancer	0.00013	0.00132	CcSEcCtD
Vorinostat—Loss of consciousness—Docetaxel—ovarian cancer	0.000128	0.0013	CcSEcCtD
Vorinostat—Weight decreased—Epirubicin—ovarian cancer	0.000128	0.00129	CcSEcCtD
Vorinostat—Hyperglycaemia—Epirubicin—ovarian cancer	0.000127	0.00129	CcSEcCtD
Vorinostat—Cough—Docetaxel—ovarian cancer	0.000127	0.00129	CcSEcCtD
Vorinostat—Chest pain—Docetaxel—ovarian cancer	0.000124	0.00126	CcSEcCtD
Vorinostat—Pancytopenia—Doxorubicin—ovarian cancer	0.000124	0.00126	CcSEcCtD
Vorinostat—Nausea—Vinorelbine—ovarian cancer	0.000124	0.00126	CcSEcCtD
Vorinostat—Neutropenia—Doxorubicin—ovarian cancer	0.000122	0.00124	CcSEcCtD
Vorinostat—Decreased appetite—Paclitaxel—ovarian cancer	0.000122	0.00124	CcSEcCtD
Vorinostat—Dry mouth—Docetaxel—ovarian cancer	0.000121	0.00123	CcSEcCtD
Vorinostat—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000121	0.00123	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000121	0.00123	CcSEcCtD
Vorinostat—Fatigue—Paclitaxel—ovarian cancer	0.000121	0.00123	CcSEcCtD
Vorinostat—Constipation—Paclitaxel—ovarian cancer	0.00012	0.00122	CcSEcCtD
Vorinostat—Infection—Docetaxel—ovarian cancer	0.000118	0.0012	CcSEcCtD
Vorinostat—Weight decreased—Doxorubicin—ovarian cancer	0.000118	0.0012	CcSEcCtD
Vorinostat—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000118	0.00119	CcSEcCtD
Vorinostat—Shock—Docetaxel—ovarian cancer	0.000117	0.00119	CcSEcCtD
Vorinostat—Thrombocytopenia—Docetaxel—ovarian cancer	0.000116	0.00118	CcSEcCtD
Vorinostat—Anorexia—Docetaxel—ovarian cancer	0.000113	0.00115	CcSEcCtD
Vorinostat—Oedema peripheral—Epirubicin—ovarian cancer	0.000111	0.00113	CcSEcCtD
Vorinostat—Body temperature increased—Paclitaxel—ovarian cancer	0.000111	0.00112	CcSEcCtD
Vorinostat—Decreased appetite—Docetaxel—ovarian cancer	0.000103	0.00105	CcSEcCtD
Vorinostat—Oedema peripheral—Doxorubicin—ovarian cancer	0.000103	0.00104	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000103	0.00104	CcSEcCtD
Vorinostat—Fatigue—Docetaxel—ovarian cancer	0.000103	0.00104	CcSEcCtD
Vorinostat—Constipation—Docetaxel—ovarian cancer	0.000102	0.00103	CcSEcCtD
Vorinostat—Chills—Epirubicin—ovarian cancer	0.000101	0.00103	CcSEcCtD
Vorinostat—Asthenia—Paclitaxel—ovarian cancer	0.000101	0.00102	CcSEcCtD
Vorinostat—Alopecia—Epirubicin—ovarian cancer	9.98e-05	0.00101	CcSEcCtD
Vorinostat—Pruritus—Paclitaxel—ovarian cancer	9.93e-05	0.00101	CcSEcCtD
Vorinostat—Dysgeusia—Epirubicin—ovarian cancer	9.62e-05	0.000976	CcSEcCtD
Vorinostat—Diarrhoea—Paclitaxel—ovarian cancer	9.6e-05	0.000973	CcSEcCtD
Vorinostat—Muscle spasms—Epirubicin—ovarian cancer	9.45e-05	0.000958	CcSEcCtD
Vorinostat—Body temperature increased—Docetaxel—ovarian cancer	9.4e-05	0.000953	CcSEcCtD
Vorinostat—Chills—Doxorubicin—ovarian cancer	9.37e-05	0.00095	CcSEcCtD
Vorinostat—Dizziness—Paclitaxel—ovarian cancer	9.28e-05	0.00094	CcSEcCtD
Vorinostat—Alopecia—Doxorubicin—ovarian cancer	9.23e-05	0.000936	CcSEcCtD
Vorinostat—Anaemia—Epirubicin—ovarian cancer	9.08e-05	0.000921	CcSEcCtD
Vorinostat—Vomiting—Paclitaxel—ovarian cancer	8.92e-05	0.000904	CcSEcCtD
Vorinostat—Dysgeusia—Doxorubicin—ovarian cancer	8.91e-05	0.000903	CcSEcCtD
Vorinostat—Syncope—Epirubicin—ovarian cancer	8.81e-05	0.000893	CcSEcCtD
Vorinostat—Leukopenia—Epirubicin—ovarian cancer	8.8e-05	0.000892	CcSEcCtD
Vorinostat—Headache—Paclitaxel—ovarian cancer	8.79e-05	0.000891	CcSEcCtD
Vorinostat—Muscle spasms—Doxorubicin—ovarian cancer	8.74e-05	0.000886	CcSEcCtD
Vorinostat—Loss of consciousness—Epirubicin—ovarian cancer	8.64e-05	0.000876	CcSEcCtD
Vorinostat—Cough—Epirubicin—ovarian cancer	8.58e-05	0.000869	CcSEcCtD
Vorinostat—Asthenia—Docetaxel—ovarian cancer	8.53e-05	0.000865	CcSEcCtD
Vorinostat—Pruritus—Docetaxel—ovarian cancer	8.41e-05	0.000853	CcSEcCtD
Vorinostat—Anaemia—Doxorubicin—ovarian cancer	8.41e-05	0.000852	CcSEcCtD
Vorinostat—Chest pain—Epirubicin—ovarian cancer	8.37e-05	0.000848	CcSEcCtD
Vorinostat—Nausea—Paclitaxel—ovarian cancer	8.33e-05	0.000845	CcSEcCtD
Vorinostat—Dry mouth—Epirubicin—ovarian cancer	8.18e-05	0.000829	CcSEcCtD
Vorinostat—Syncope—Doxorubicin—ovarian cancer	8.16e-05	0.000827	CcSEcCtD
Vorinostat—Leukopenia—Doxorubicin—ovarian cancer	8.14e-05	0.000825	CcSEcCtD
Vorinostat—Diarrhoea—Docetaxel—ovarian cancer	8.14e-05	0.000825	CcSEcCtD
Vorinostat—Loss of consciousness—Doxorubicin—ovarian cancer	7.99e-05	0.00081	CcSEcCtD
Vorinostat—Infection—Epirubicin—ovarian cancer	7.97e-05	0.000808	CcSEcCtD
Vorinostat—Cough—Doxorubicin—ovarian cancer	7.94e-05	0.000804	CcSEcCtD
Vorinostat—Shock—Epirubicin—ovarian cancer	7.89e-05	0.0008	CcSEcCtD
Vorinostat—Dizziness—Docetaxel—ovarian cancer	7.86e-05	0.000797	CcSEcCtD
Vorinostat—Thrombocytopenia—Epirubicin—ovarian cancer	7.85e-05	0.000796	CcSEcCtD
Vorinostat—Chest pain—Doxorubicin—ovarian cancer	7.74e-05	0.000785	CcSEcCtD
Vorinostat—Anorexia—Epirubicin—ovarian cancer	7.65e-05	0.000775	CcSEcCtD
Vorinostat—Dry mouth—Doxorubicin—ovarian cancer	7.57e-05	0.000767	CcSEcCtD
Vorinostat—Vomiting—Docetaxel—ovarian cancer	7.56e-05	0.000766	CcSEcCtD
Vorinostat—Headache—Docetaxel—ovarian cancer	7.45e-05	0.000755	CcSEcCtD
Vorinostat—Infection—Doxorubicin—ovarian cancer	7.37e-05	0.000747	CcSEcCtD
Vorinostat—Shock—Doxorubicin—ovarian cancer	7.3e-05	0.00074	CcSEcCtD
Vorinostat—Thrombocytopenia—Doxorubicin—ovarian cancer	7.27e-05	0.000737	CcSEcCtD
Vorinostat—Anorexia—Doxorubicin—ovarian cancer	7.07e-05	0.000717	CcSEcCtD
Vorinostat—Nausea—Docetaxel—ovarian cancer	7.06e-05	0.000716	CcSEcCtD
Vorinostat—Decreased appetite—Epirubicin—ovarian cancer	6.97e-05	0.000707	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Epirubicin—ovarian cancer	6.92e-05	0.000702	CcSEcCtD
Vorinostat—Fatigue—Epirubicin—ovarian cancer	6.92e-05	0.000701	CcSEcCtD
Vorinostat—Constipation—Epirubicin—ovarian cancer	6.86e-05	0.000695	CcSEcCtD
Vorinostat—Decreased appetite—Doxorubicin—ovarian cancer	6.45e-05	0.000654	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Doxorubicin—ovarian cancer	6.41e-05	0.000649	CcSEcCtD
Vorinostat—Fatigue—Doxorubicin—ovarian cancer	6.4e-05	0.000649	CcSEcCtD
Vorinostat—Constipation—Doxorubicin—ovarian cancer	6.35e-05	0.000643	CcSEcCtD
Vorinostat—Body temperature increased—Epirubicin—ovarian cancer	6.34e-05	0.000643	CcSEcCtD
Vorinostat—Body temperature increased—Doxorubicin—ovarian cancer	5.87e-05	0.000595	CcSEcCtD
Vorinostat—Asthenia—Epirubicin—ovarian cancer	5.76e-05	0.000583	CcSEcCtD
Vorinostat—Pruritus—Epirubicin—ovarian cancer	5.67e-05	0.000575	CcSEcCtD
Vorinostat—Diarrhoea—Epirubicin—ovarian cancer	5.49e-05	0.000556	CcSEcCtD
Vorinostat—Asthenia—Doxorubicin—ovarian cancer	5.32e-05	0.00054	CcSEcCtD
Vorinostat—Dizziness—Epirubicin—ovarian cancer	5.3e-05	0.000538	CcSEcCtD
Vorinostat—Pruritus—Doxorubicin—ovarian cancer	5.25e-05	0.000532	CcSEcCtD
Vorinostat—Vomiting—Epirubicin—ovarian cancer	5.1e-05	0.000517	CcSEcCtD
Vorinostat—Diarrhoea—Doxorubicin—ovarian cancer	5.08e-05	0.000515	CcSEcCtD
Vorinostat—Headache—Epirubicin—ovarian cancer	5.03e-05	0.000509	CcSEcCtD
Vorinostat—Dizziness—Doxorubicin—ovarian cancer	4.91e-05	0.000497	CcSEcCtD
Vorinostat—Nausea—Epirubicin—ovarian cancer	4.76e-05	0.000483	CcSEcCtD
Vorinostat—Vomiting—Doxorubicin—ovarian cancer	4.72e-05	0.000478	CcSEcCtD
Vorinostat—Headache—Doxorubicin—ovarian cancer	4.65e-05	0.000471	CcSEcCtD
Vorinostat—Nausea—Doxorubicin—ovarian cancer	4.41e-05	0.000447	CcSEcCtD
Vorinostat—HDAC2—Gene Expression—ESR1—ovarian cancer	7.72e-06	5.1e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—MYC—ovarian cancer	7.71e-06	5.1e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—CASP3—ovarian cancer	7.71e-06	5.1e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—IL2—ovarian cancer	7.7e-06	5.09e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—IL6ST—ovarian cancer	7.66e-06	5.06e-05	CbGpPWpGaD
Vorinostat—NCOR1—Gene Expression—MYC—ovarian cancer	7.64e-06	5.05e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—STAT3—ovarian cancer	7.64e-06	5.05e-05	CbGpPWpGaD
Vorinostat—HDAC6—Disease—AKT1—ovarian cancer	7.64e-06	5.05e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—ERBB2—ovarian cancer	7.63e-06	5.04e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—NRAS—ovarian cancer	7.62e-06	5.04e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—VEGFA—ovarian cancer	7.58e-06	5.01e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—CDKN1B—ovarian cancer	7.56e-06	5e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—TP53—ovarian cancer	7.56e-06	4.99e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—MAPK1—ovarian cancer	7.56e-06	4.99e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—EGFR—ovarian cancer	7.55e-06	4.99e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—MAPK1—ovarian cancer	7.55e-06	4.99e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—EGFR—ovarian cancer	7.54e-06	4.99e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—MAPK1—ovarian cancer	7.53e-06	4.98e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—MTOR—ovarian cancer	7.53e-06	4.98e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—PIK3CB—ovarian cancer	7.53e-06	4.98e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—CCND1—ovarian cancer	7.51e-06	4.96e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—STAT3—ovarian cancer	7.51e-06	4.96e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—NRAS—ovarian cancer	7.49e-06	4.95e-05	CbGpPWpGaD
Vorinostat—HDAC4—Disease—IL6—ovarian cancer	7.49e-06	4.95e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—CAV1—ovarian cancer	7.44e-06	4.92e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—CTNNB1—ovarian cancer	7.43e-06	4.91e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—PIK3CG—ovarian cancer	7.36e-06	4.87e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—APC—ovarian cancer	7.36e-06	4.87e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—PIK3CA—ovarian cancer	7.3e-06	4.82e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—MAPK3—ovarian cancer	7.3e-06	4.82e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—MMP9—ovarian cancer	7.29e-06	4.82e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—PTEN—ovarian cancer	7.25e-06	4.79e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—CXCL8—ovarian cancer	7.24e-06	4.78e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—HRAS—ovarian cancer	7.23e-06	4.78e-05	CbGpPWpGaD
Vorinostat—HDAC8—Disease—HRAS—ovarian cancer	7.22e-06	4.77e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—MAPK3—ovarian cancer	7.17e-06	4.74e-05	CbGpPWpGaD
Vorinostat—NCOR1—Metabolism—PTEN—ovarian cancer	7.15e-06	4.73e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—CTNNB1—ovarian cancer	7.14e-06	4.72e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—KRAS—ovarian cancer	7.14e-06	4.72e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—KRAS—ovarian cancer	7.13e-06	4.71e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—KRAS—ovarian cancer	7.12e-06	4.7e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—MYC—ovarian cancer	7.1e-06	4.69e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—PPP2R1A—ovarian cancer	7.09e-06	4.68e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—CDKN1B—ovarian cancer	7.07e-06	4.67e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—IL6ST—ovarian cancer	7.05e-06	4.66e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—ERBB2—ovarian cancer	7.01e-06	4.63e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—VEGFA—ovarian cancer	7e-06	4.62e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—MYC—ovarian cancer	6.97e-06	4.61e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—PTEN—ovarian cancer	6.96e-06	4.6e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—MAPK1—ovarian cancer	6.94e-06	4.59e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—EGFR—ovarian cancer	6.94e-06	4.59e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—STAT3—ovarian cancer	6.93e-06	4.58e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—CASP3—ovarian cancer	6.93e-06	4.58e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—MTOR—ovarian cancer	6.92e-06	4.57e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—PIK3CB—ovarian cancer	6.92e-06	4.57e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—IL6—ovarian cancer	6.92e-06	4.57e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—IL2—ovarian cancer	6.92e-06	4.57e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—NRAS—ovarian cancer	6.91e-06	4.57e-05	CbGpPWpGaD
Vorinostat—HDAC8—Disease—IL6—ovarian cancer	6.91e-06	4.57e-05	CbGpPWpGaD
Vorinostat—HDAC4—Disease—AKT1—ovarian cancer	6.91e-06	4.56e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—MAPK1—ovarian cancer	6.82e-06	4.51e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—EGFR—ovarian cancer	6.82e-06	4.51e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—APC—ovarian cancer	6.78e-06	4.48e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—HRAS—ovarian cancer	6.75e-06	4.46e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—CCND1—ovarian cancer	6.74e-06	4.46e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—CTNNB1—ovarian cancer	6.68e-06	4.41e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—CXCL8—ovarian cancer	6.65e-06	4.4e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—MAPK3—ovarian cancer	6.62e-06	4.37e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—KRAS—ovarian cancer	6.56e-06	4.33e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—PIK3CA—ovarian cancer	6.56e-06	4.33e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—PIK3CA—ovarian cancer	6.55e-06	4.33e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—MMP9—ovarian cancer	6.55e-06	4.33e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—VEGFA—ovarian cancer	6.54e-06	4.32e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—PIK3CA—ovarian cancer	6.54e-06	4.32e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—PTEN—ovarian cancer	6.51e-06	4.3e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—CDKN1B—ovarian cancer	6.5e-06	4.29e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—STAT3—ovarian cancer	6.48e-06	4.28e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—PIK3CD—ovarian cancer	6.47e-06	4.28e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—NRAS—ovarian cancer	6.46e-06	4.27e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—IL6—ovarian cancer	6.46e-06	4.27e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—KRAS—ovarian cancer	6.44e-06	4.26e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—MYC—ovarian cancer	6.44e-06	4.25e-05	CbGpPWpGaD
Vorinostat—HDAC1—Gene Expression—MAPK3—ovarian cancer	6.41e-06	4.23e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—AKT1—ovarian cancer	6.38e-06	4.22e-05	CbGpPWpGaD
Vorinostat—HDAC8—Disease—AKT1—ovarian cancer	6.37e-06	4.21e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—CASP3—ovarian cancer	6.37e-06	4.21e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—IL2—ovarian cancer	6.36e-06	4.2e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—TP53—ovarian cancer	6.33e-06	4.19e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—TP53—ovarian cancer	6.32e-06	4.18e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—MAPK1—ovarian cancer	6.3e-06	4.16e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—EGFR—ovarian cancer	6.3e-06	4.16e-05	CbGpPWpGaD
Vorinostat—NR0B1—Gene Expression—AKT1—ovarian cancer	6.23e-06	4.12e-05	CbGpPWpGaD
Vorinostat—HDAC1—Gene Expression—MYC—ovarian cancer	6.23e-06	4.12e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—STAT3—ovarian cancer	6.23e-06	4.11e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—NRAS—ovarian cancer	6.21e-06	4.1e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—CCND1—ovarian cancer	6.2e-06	4.09e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—MAPK3—ovarian cancer	6.19e-06	4.09e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—CTNNB1—ovarian cancer	6.14e-06	4.05e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—HRAS—ovarian cancer	6.07e-06	4.01e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—HRAS—ovarian cancer	6.06e-06	4e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—HRAS—ovarian cancer	6.05e-06	4e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—PIK3CA—ovarian cancer	6.02e-06	3.98e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—MYC—ovarian cancer	6.02e-06	3.98e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—MMP9—ovarian cancer	6.02e-06	3.98e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—PTEN—ovarian cancer	5.98e-06	3.95e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—AKT1—ovarian cancer	5.96e-06	3.94e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—PIK3CD—ovarian cancer	5.96e-06	3.94e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—MAPK3—ovarian cancer	5.95e-06	3.93e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—KRAS—ovarian cancer	5.95e-06	3.93e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—PIK3CA—ovarian cancer	5.92e-06	3.91e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—MAPK1—ovarian cancer	5.89e-06	3.89e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—EGFR—ovarian cancer	5.89e-06	3.89e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—VEGFA—ovarian cancer	5.88e-06	3.88e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—STAT3—ovarian cancer	5.82e-06	3.85e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—NRAS—ovarian cancer	5.81e-06	3.84e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—IL6—ovarian cancer	5.81e-06	3.84e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—IL6—ovarian cancer	5.8e-06	3.83e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—MYC—ovarian cancer	5.79e-06	3.82e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—TP53—ovarian cancer	5.73e-06	3.79e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—ERBB2—ovarian cancer	5.72e-06	3.78e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—MAPK1—ovarian cancer	5.66e-06	3.74e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—EGFR—ovarian cancer	5.66e-06	3.74e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—PIK3CB—ovarian cancer	5.64e-06	3.73e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—MTOR—ovarian cancer	5.64e-06	3.73e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—TERT—ovarian cancer	5.63e-06	3.72e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—HRAS—ovarian cancer	5.57e-06	3.68e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—KRAS—ovarian cancer	5.56e-06	3.68e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—MAPK3—ovarian cancer	5.56e-06	3.67e-05	CbGpPWpGaD
Vorinostat—HDAC3—Metabolism—PIK3CA—ovarian cancer	5.49e-06	3.63e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—HRAS—ovarian cancer	5.48e-06	3.62e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—PIK3CA—ovarian cancer	5.46e-06	3.61e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—CXCL8—ovarian cancer	5.42e-06	3.58e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—MYC—ovarian cancer	5.41e-06	3.57e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—VEGFA—ovarian cancer	5.4e-06	3.57e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—AKT1—ovarian cancer	5.36e-06	3.54e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—STAT3—ovarian cancer	5.35e-06	3.53e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—AKT1—ovarian cancer	5.35e-06	3.53e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—KRAS—ovarian cancer	5.35e-06	3.53e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—AKT1—ovarian cancer	5.34e-06	3.53e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—NRAS—ovarian cancer	5.34e-06	3.53e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—IL6—ovarian cancer	5.34e-06	3.53e-05	CbGpPWpGaD
Vorinostat—NCOR1—Gene Expression—AKT1—ovarian cancer	5.3e-06	3.5e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—CDKN1B—ovarian cancer	5.29e-06	3.5e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—MAPK1—ovarian cancer	5.29e-06	3.5e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—EGFR—ovarian cancer	5.29e-06	3.5e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—TP53—ovarian cancer	5.29e-06	3.49e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—ERBB2—ovarian cancer	5.26e-06	3.48e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—IL6—ovarian cancer	5.24e-06	3.46e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—CAV1—ovarian cancer	5.21e-06	3.44e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—PIK3CB—ovarian cancer	5.19e-06	3.43e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—MTOR—ovarian cancer	5.19e-06	3.43e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—CASP3—ovarian cancer	5.19e-06	3.43e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—IL2—ovarian cancer	5.18e-06	3.42e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—PIK3CA—ovarian cancer	5.11e-06	3.38e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—MAPK3—ovarian cancer	5.11e-06	3.38e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—HRAS—ovarian cancer	5.06e-06	3.34e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—CCND1—ovarian cancer	5.05e-06	3.34e-05	CbGpPWpGaD
Vorinostat—NCOR1—Metabolism—PIK3CA—ovarian cancer	5.05e-06	3.33e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—ESR1—ovarian cancer	5.02e-06	3.32e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—CTNNB1—ovarian cancer	5e-06	3.31e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—KRAS—ovarian cancer	5e-06	3.3e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—MYC—ovarian cancer	4.97e-06	3.28e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—TP53—ovarian cancer	4.94e-06	3.27e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—IL6ST—ovarian cancer	4.94e-06	3.26e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—AKT1—ovarian cancer	4.92e-06	3.25e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—PIK3CA—ovarian cancer	4.91e-06	3.25e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—MMP9—ovarian cancer	4.9e-06	3.24e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—PTEN—ovarian cancer	4.88e-06	3.22e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—CDKN1B—ovarian cancer	4.87e-06	3.22e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—MAPK1—ovarian cancer	4.86e-06	3.21e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—EGFR—ovarian cancer	4.86e-06	3.21e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—IL6—ovarian cancer	4.84e-06	3.2e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—AKT1—ovarian cancer	4.84e-06	3.2e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—APC—ovarian cancer	4.74e-06	3.14e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—PIK3CG—ovarian cancer	4.74e-06	3.14e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—HRAS—ovarian cancer	4.73e-06	3.13e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—CTNNB1—ovarian cancer	4.6e-06	3.04e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—KRAS—ovarian cancer	4.59e-06	3.03e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—PIK3CA—ovarian cancer	4.59e-06	3.03e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—HRAS—ovarian cancer	4.54e-06	3e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—IL6—ovarian cancer	4.53e-06	2.99e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—PTEN—ovarian cancer	4.49e-06	2.96e-05	CbGpPWpGaD
Vorinostat—HDAC3—Metabolism—AKT1—ovarian cancer	4.49e-06	2.96e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—AKT1—ovarian cancer	4.46e-06	2.95e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—TP53—ovarian cancer	4.44e-06	2.94e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—VEGFA—ovarian cancer	4.4e-06	2.91e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—STAT3—ovarian cancer	4.36e-06	2.88e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—NRAS—ovarian cancer	4.35e-06	2.87e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—IL6—ovarian cancer	4.35e-06	2.87e-05	CbGpPWpGaD
Vorinostat—HDAC1—Gene Expression—AKT1—ovarian cancer	4.32e-06	2.86e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—HRAS—ovarian cancer	4.25e-06	2.81e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—PIK3CA—ovarian cancer	4.22e-06	2.79e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—AKT1—ovarian cancer	4.18e-06	2.76e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—PIK3CD—ovarian cancer	4.17e-06	2.76e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—MAPK3—ovarian cancer	4.17e-06	2.75e-05	CbGpPWpGaD
Vorinostat—HDAC2—Gene Expression—MAPK3—ovarian cancer	4.13e-06	2.73e-05	CbGpPWpGaD
Vorinostat—NCOR1—Metabolism—AKT1—ovarian cancer	4.12e-06	2.72e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—TP53—ovarian cancer	4.08e-06	2.7e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—IL6—ovarian cancer	4.07e-06	2.69e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—MYC—ovarian cancer	4.05e-06	2.68e-05	CbGpPWpGaD
Vorinostat—HDAC2—Gene Expression—MYC—ovarian cancer	4.02e-06	2.65e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—STAT3—ovarian cancer	4.01e-06	2.65e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—AKT1—ovarian cancer	4.01e-06	2.65e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—NRAS—ovarian cancer	4e-06	2.65e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—MAPK1—ovarian cancer	3.96e-06	2.62e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—EGFR—ovarian cancer	3.96e-06	2.62e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—HRAS—ovarian cancer	3.9e-06	2.58e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—MAPK3—ovarian cancer	3.83e-06	2.53e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—AKT1—ovarian cancer	3.75e-06	2.48e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—KRAS—ovarian cancer	3.74e-06	2.47e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—IL6—ovarian cancer	3.74e-06	2.47e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—MYC—ovarian cancer	3.73e-06	2.46e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—ERBB2—ovarian cancer	3.68e-06	2.43e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—MAPK1—ovarian cancer	3.65e-06	2.41e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—EGFR—ovarian cancer	3.65e-06	2.41e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—MTOR—ovarian cancer	3.64e-06	2.4e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—PIK3CB—ovarian cancer	3.64e-06	2.4e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—CXCL8—ovarian cancer	3.49e-06	2.31e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—AKT1—ovarian cancer	3.45e-06	2.28e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—KRAS—ovarian cancer	3.44e-06	2.28e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—PIK3CA—ovarian cancer	3.44e-06	2.27e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—CDKN1B—ovarian cancer	3.41e-06	2.25e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—CASP3—ovarian cancer	3.34e-06	2.21e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—IL2—ovarian cancer	3.34e-06	2.21e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—TP53—ovarian cancer	3.33e-06	2.2e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—CCND1—ovarian cancer	3.25e-06	2.15e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—CTNNB1—ovarian cancer	3.22e-06	2.13e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—HRAS—ovarian cancer	3.18e-06	2.1e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—PIK3CA—ovarian cancer	3.16e-06	2.09e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—MMP9—ovarian cancer	3.16e-06	2.09e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—PTEN—ovarian cancer	3.14e-06	2.08e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—IL6—ovarian cancer	3.05e-06	2.01e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—HRAS—ovarian cancer	2.93e-06	1.94e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—VEGFA—ovarian cancer	2.84e-06	1.88e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—STAT3—ovarian cancer	2.81e-06	1.86e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—AKT1—ovarian cancer	2.81e-06	1.86e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—NRAS—ovarian cancer	2.8e-06	1.85e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—IL6—ovarian cancer	2.8e-06	1.85e-05	CbGpPWpGaD
Vorinostat—HDAC2—Gene Expression—AKT1—ovarian cancer	2.78e-06	1.84e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—MAPK3—ovarian cancer	2.68e-06	1.77e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—MYC—ovarian cancer	2.61e-06	1.73e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—AKT1—ovarian cancer	2.59e-06	1.71e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—MAPK1—ovarian cancer	2.55e-06	1.69e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—EGFR—ovarian cancer	2.55e-06	1.69e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—KRAS—ovarian cancer	2.41e-06	1.59e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—PIK3CA—ovarian cancer	2.22e-06	1.46e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—TP53—ovarian cancer	2.14e-06	1.42e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—HRAS—ovarian cancer	2.05e-06	1.36e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—IL6—ovarian cancer	1.96e-06	1.3e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—AKT1—ovarian cancer	1.81e-06	1.2e-05	CbGpPWpGaD
